216 related articles for article (PubMed ID: 7826529)
1. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Topalian SL
Curr Opin Immunol; 1994 Oct; 6(5):741-5. PubMed ID: 7826529
[TBL] [Abstract][Full Text] [Related]
2. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
3. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
Wang RF
Trends Immunol; 2001 May; 22(5):269-76. PubMed ID: 11323286
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
5. CD4 T cells and their role in antitumor immune responses.
Toes RE; Ossendorp F; Offringa R; Melief CJ
J Exp Med; 1999 Mar; 189(5):753-6. PubMed ID: 10049938
[No Abstract] [Full Text] [Related]
6. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
7. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
8. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
9. Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
Ostrand-Rosenberg S
Curr Opin Immunol; 1994 Oct; 6(5):722-7. PubMed ID: 7826527
[TBL] [Abstract][Full Text] [Related]
10. The role of CD4+ T cell responses in antitumor immunity.
Pardoll DM; Topalian SL
Curr Opin Immunol; 1998 Oct; 10(5):588-94. PubMed ID: 9794842
[TBL] [Abstract][Full Text] [Related]
11. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
[TBL] [Abstract][Full Text] [Related]
12. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
13. Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells.
Nicholl M; Lodge A; Brown I; Sugg SL; Shilyansky J
J Pediatr Surg; 2004 Jun; 39(6):941-6; discussion 941-6. PubMed ID: 15185230
[TBL] [Abstract][Full Text] [Related]
14. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
15. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
16. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
Depontieu FR; Qian J; Zarling AL; McMiller TL; Salay TM; Norris A; English AM; Shabanowitz J; Engelhard VH; Hunt DF; Topalian SL
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12073-8. PubMed ID: 19581576
[TBL] [Abstract][Full Text] [Related]
17. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
18. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A; Lorvik KB; Bogen B
Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
[TBL] [Abstract][Full Text] [Related]
19. [RNA-loaded dendritic cells].
Hinoda Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():613-8. PubMed ID: 15861719
[No Abstract] [Full Text] [Related]
20. Molecular cloning and characterization of MHC class I- and II-restricted tumor antigens recognized by T cells.
Wang RF
Curr Protoc Immunol; 2009 Feb; Chapter 20():20.10.1-20.10.29. PubMed ID: 19235768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
